Evidence map›Paper›PMID 28250687›Full record

ArticleJournal of natural science, biology, and medicine

Novel hydroxamates potentiated

Maneesh Paul-Satyaseela, Periasamy Hariharan, Thirunavukkarasu Bharani, Jonathan S Franklyne, Thangapazham Selvakumar, Kuppusamy Bharathimohan, Chenniappan Vinoth Kumar, Virendra Kachhadia, Shridhar Narayanan, Sridharan Rajagopal and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Journal of natural science, biology, and medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Maneesh Paul-SatyaseelaDrug Discovery Research, Orchid Pharma Ltd., Chennai, Tamil Nadu, India; Samrud Foundation for Health and Research/St. Martha's Hospital, Bengaluru, Karnataka, India.
Periasamy HariharanDrug Discovery Research, Orchid Pharma Ltd., Chennai, Tamil Nadu, India.
Thirunavukkarasu BharaniDrug Discovery Research, Orchid Pharma Ltd., Chennai, Tamil Nadu, India.
Jonathan S FranklyneDrug Discovery Research, Orchid Pharma Ltd., Chennai, Tamil Nadu, India.
Thangapazham SelvakumarDrug Discovery Research, Orchid Pharma Ltd., Chennai, Tamil Nadu, India.
Kuppusamy BharathimohanDrug Discovery Research, Orchid Pharma Ltd., Chennai, Tamil Nadu, India.
Chenniappan Vinoth KumarDrug Discovery Research, Orchid Pharma Ltd., Chennai, Tamil Nadu, India.
Virendra KachhadiaDrug Discovery Research, Orchid Pharma Ltd., Chennai, Tamil Nadu, India.
Shridhar NarayananFoundation for Neglected Disease Research, Sri Krishnadevaraya Research Centre, Sir M. Visvesvaraya Institute of Technology, Bengaluru, Karnataka, India.
Sridharan RajagopalJubilant Biosys Ltd., 96, Industrial Suburb 2nd Stage, Yeshwantpur, Bengaluru, Karnataka, India.
Gopalan BalasubramanianDrug Discovery Research, Orchid Pharma Ltd., Chennai, Tamil Nadu, India.
Orchid Pharma (India) · INFoundation for Neglected Disease Research · INJubilant Life Sciences (India) · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A set of 12 novel hydroxamate compounds (NHCs), structurally designed as inhibitors of histone deacetylase (HDAC) enzyme, were synthesized at our facility. These were adamantane derivatives with

Indexed as

Antifungalscandidiasisfluconazolehistone deacetylase inhibitorshydroxamates

Identifiers

PMID28250687
PMCPMC5320813
OpenAlexW2575616070

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.